Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA

Mantle cell lymphoma (MCL) is an aggressive B-non-Hodgkin lymphoma with generally poor outcome. MCL is characterized by an aberrantly high cyclin D1-driven CDK4 activity. New molecular targeted therapies such ...

Source: Journal of Hematology and Oncology - September 4, 2018 Category: Hematology Authors: Simon Heine, Markus Kleih, Neus Gim énez, Kathrin Böpple, German Ott, Dolors Colomer, Walter E. Aulitzky, Heiko van der Kuip and Elisabeth Silkenstedt Tags: Research Source Type: research